9 companies

Showing 1–9 of 9 companies

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is an RNAi therapeutics company developing gene-silencing medicines for TTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria, from discovery through commercialisation.

Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company developing Helicons™, a class of alpha-helical peptides designed to target historically undruggable intracellular protein targets for cancer and other diseases.

Pulmovant

Pulmovant is a clinical-stage biotechnology company developing inhaled therapies for pulmonary diseases, with a lead candidate in Phase 2 trials for pulmonary hypertension.

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company developing genetic medicines, with nine approved therapies and operations in more than 70 countries.

Ipsen Pharma Singapore PTE. LTD.

Ipsen Pharma Singapore is the local arm of Ipsen, a global biopharmaceutical company specialising in oncology, rare disease, and neuroscience across 88 countries.

Regeneron Pharmaceuticals, Inc (USA)

Regeneron Pharmaceuticals is a US-based biotechnology company that invents, develops, and commercializes medicines for serious diseases, with capabilities in antibody discovery and genetic medicine.

Moderna

Moderna is a biotechnology company that develops mRNA-based medicines, including vaccines for COVID-19 and RSV, with a pipeline spanning infectious diseases, oncology, rare diseases, and other therapeutic areas.

Adaptive Biotechnologies

Adaptive Biotechnologies decodes the adaptive immune system's genetics to build diagnostic and therapeutic products, including the clonoSEQ test for minimal residual disease in blood cancer.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers and commercializes therapeutics in virology, oncology, and inflammatory diseases, with operations in over 35 countries.